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Aims: Metformin is renally excreted and has been associated with the development of lactic acido-
sis. Although current advice is to omit metformin during illnesses that may increase the risk of
acute kidney injury (AKI), the evidence supporting this is lacking. We investigated the relationship
between AKI, lactate concentrations and the risk of lactic acidosis in those exposed to metformin.
Materials and Methods: We undertook a population-based case-control study of lactic acidosis
in 1746 participants with Type 2 diabetes and 846 individuals without diabetes with clinically
measured lactates with and without AKI between 1994 and 2014. AKI was stratified by sever-
ity according to “Kidney Disease: Improving Global Outcomes” guidelines. Mixed-effects logis-
tic and linear regression were used to analyse lactic acidosis risk and lactate concentrations,
respectively.
Results: Eighty-two cases of lactic acidosis were identified. In Type 2 diabetes, those treated
with metformin had a greater incidence of lactic acidosis [45.7 per 100 000 patient years; 95%
confidence interval (CI) 35.9-58.3] compared to those not exposed to this drug (11.8 per
100 000 patient years; 95% CI 4.9-28.5). Lactate concentrations were 0.34 mmol/L higher in
the metformin-exposed cohort (P < .001). The risk of lactic acidosis was higher in metformin
users [odds ratio (OR) 2.3; P = .002] and increased with AKI severity (stage 1: OR 3.0,
P = .002; stage 2: OR 9.4, P < .001; stage 3: OR 16.1, P < .001).
Conclusions: A clear association was found between metformin, lactate accumulation and the
development of lactic acidosis. This relationship is strongest in those with AKI. These results
provide robust evidence to support current recommendations to omit metformin in any illness
that may precipitate AKI.
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1 | INTRODUCTION
Metformin is the first-line treatment of Type 2 diabetes recom-
mended in both national and international guidelines. Metformin has
an extremely favourable clinical profile: it is weight neutral, does not
cause hypoglycaemia, and is superior to equivalent sulphonylurea or
insulin therapy in the reduction of cardiovascular and all-cause mor-
tality.1 However, adverse reactions to this drug are common, with as
many as 30% of metformin users developing gastrointestinal side-
effects.2
One risk associated with metformin use is the development of
lactic acidosis, a potentially fatal condition. Lactic acidosis is defined
as an elevated blood lactate concentration (>5 mmol/L) along with a
decreased blood pH (<7.35) and an increased anion gap.3 The exact
mechanism responsible for this condition is not fully understood;
however, it is likely a consequence of metformin inhibition of the
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mitochondrial respiratory chain, thereby promoting anaerobic metab-
olism and lactate accumulation.4 This condition has a mortality of up
to 50% per episode,5 and is believed to occur at a rate of about 1 per
23 000 to 30 000 person-years of metformin use.6
Epidemiological studies have investigated the factors contribut-
ing to the development of lactic acidosis associated with metformin
use.3,7–10 As metformin is exclusively excreted renally, the emphasis
of these studies has been the role of chronic kidney disease (CKD) in
the development of lactic acidosis.8,9 Due to conflicting results there
is not yet a consensus on their interpretation, which has led to the
suggestion that it may be appropriate to relax current metformin-
prescribing practices in those with chronic renal impairment.6,11
Nonetheless, the potential risk of metformin in severe renal disease
has again been recently highlighted.12
There is, however, limited evidence of a link between metformin-
induced lactic acidosis and alterations in metformin pharmacokinetics.
Case reports of acute metformin overdoses have shown that sudden
increases in plasma metformin concentrations precede the develop-
ment of lactic acidosis.13,14 Dehydration and acute kidney injury (AKI)
have been cited as precipitating factors in the development of lactic
acidosis in those established on stable metformin therapy.15–18 The
current advice advocated by the UK Renal Association and NHS Eng-
land, as part of the “Think Kidneys” initiative (http://www.
thinkkidneys.nhs.uk), and by a number of other guidelines, is that
metformin should be omitted during illness that may predispose to
AKI, such as diarrhoea and vomiting.4 However, the evidence availa-
ble concerning the impact of acute derangements in renal function
upon the risk of precipitating metformin-associated lactic acidosis is
limited to small case series and has not been the subject of any
population-based epidemiological analysis. Consequently, we used a
large population cohort, for whom biochemistry and prescribing data
were available, to investigate the effect of AKI on plasma lactate con-
centrations and lactic acidosis in users and non-users of metformin.
In addition, AKI was stratified according to severity (stages 1-3) in
order to better characterise any observed relationship.
2 | MATERIALS AND METHODS
2.1 | Study setting and design
A population-based case-control study of lactic acidosis was con-
ducted in Tayside, UK. Using the Genetics of Diabetes Audit and
Research Tayside (GoDARTs) cohort, we identified a base population
of approximately 18 000 individuals.18 Participants were eligible for
inclusion if they were over 18 years old with no history of Type
1 diabetes.
GoDARTs participants with a measured lactate concentration
were included in the source population of this study. Lactate concen-
trations were measured on clinical grounds with no fixed duration
between measurements. This population was observed between
January 1, 1994 and March 1, 2014. All lactic acidosis events, defined
as a lactate > 5 mmol/L coincident with bicarbonate <18 mmol/L,
were identified retrospectively from this database. These cases were
compared with the remaining source population who had at least one
lactate measure but no incident lactic acidosis. For each lactate meas-
ure, individuals were defined as being metformin treated if they
encashed a metformin prescription within the 3 months before the
lactate measure. Within the population of participants without diabe-
tes, no metformin prescriptions were observed.
Participants with AKI were identified and stratified by severity
according to the current “Kidney Disease: Improving Global Out-
comes (KDIGO)” guidelines, which are based on serum creatinine.19
The urine output criterion for the diagnosis of AKI was omitted. Stage
1 AKI was defined as a creatinine rise of ≥26.5 μmol/L within
48 hours or a creatinine 1.5 to 1.9 times the baseline reference value.
Stage 2 AKI was defined as 2.0 to 2.9 times increase in baseline cre-
atinine. Stage 3 AKI was defined as ≥3.0 times baseline creatinine
increase or increases of ≥354 μmol/L. Patients were coded as 1 to
3 based upon AKI staging, and 0 (AKI stage 0) in the absence of AKI.
In accordance with the UK Renal Association guidance, the reference
creatinine was defined as the lowest creatinine value recorded within
3 months before the event or estimated from the nadir creatinine fol-
lowing AKI recovery.20–22 Patients were also grouped into categories
by baseline estimated glomerular filtration rate (eGFR) ranges
≥60 mL/min/1.73 m2 (CKD stages 1 and 2), eGFR ranges 30 to
59 mL/min/1.73 m2 (CKD stages 3A and 3B), and eGFR ranges
<30 mL/min/1.73 m2 (CKD stages 4 and 5).19
2.2 | Statistical analysis
Baseline participant characteristics of study participants were col-
lected (Table 1) and compared using ANOVA for continuous measures
and chi-squared test for categorical measures. A Cox proportional
hazard model was used to investigate mortality following the first lac-
tate measurement. Crude incidence rates for participants without dia-
betes and with Type 2 diabetes (metformin users and non-users)
were calculated along with 95% confidence intervals (95% CI) for the
upper and lower limits based on the Poisson distribution. The base
GoDARTs population was used as the denominator for this measure.
Exposure was calculated from January 1, 1994 to the end of the
study, the date of the first episode of lactic acidosis or the date of
death. Data for each individual were censored following either of
these events. During this observational period, patients encashing at
least one metformin prescription were considered “metformin-
exposed.” Fisher’s exact test was used to calculate differences in inci-
dence rates.
The primary outcome, lactic acidosis, was analysed using a
mixed-effects logistic regression analysis. A mixed linear regression
model was then fitted to assess the effect of selected covariates
upon the continuous variable, lactate (mmol/L). Mixed-effects models
are used for grouped or clustered data where observations within a
cluster cannot be assumed to be independent. These models include
both fixed-effects, to estimate average outcomes across the popula-
tion, and random-effects, that represent variation between the sub-
groups of data points. Random effects were included when the intra-
class correlation coefficient ≥0.1.23 Likelihood ratio testing was used
to confirm the suitability of mixed-effects models compared with
standard regression.
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A backwards-stepwise method was used for model selection.
Covariate terms were excluded if they were found to be non-
significant within the model (P > .05). The covariates selected as can-
didate terms for inclusion in the models were the categorical vari-
ables metformin use, gender, AKI stage and CKD stage, and the
continuous variables C-reactive protein (CRP; mmol/L) and age at
point of lactate measurement. CRP was included as a covariate as a
measure of infection or inflammation that might have precipitated
the lactate measurement. The last recorded HbA1c (Diabetes Control
and Complications Trial %) was used in the analysis of data from only
patients with diabetes. Metformin was treated as a random coeffi-
cient within the mixed models permitting alternating uses throughout
the study period. An interaction term between AKI stage and the use
of metformin was also incorporated into a mixed linear regression
analysis of lactate concentrations in the cohort of patients with Type
2 diabetes.
3 | RESULTS
3.1 | Study cohort and participant characteristics
Lactate measurements were available for 1746 patients with Type
2 diabetes and 846 people without diabetes (Table 1). One-hundred
and fourteen individuals (10.1% of metformin users) had lactate levels
recorded both during periods of metformin use and non-use. In this
sub-cohort, mean lactate measurements were 2.14 mmol/L when not
exposed to metformin and 2.67 mmol/L when exposed to this drug
(mean difference 0.52 mmol/L; 95% CI 0.17-0.89; P = .004).
The mean number of measurements per person within each
group was 1.9 (SD 1.6), 2.3 (SD 2.2) and 2.4 (SD 2.3) in the non-
diabetic group, non-metformin users and metformin users, respec-
tively [Kruskal–Wallis H-test; χ2(2) = 28.6; P = .0001]. Seven indivi-
duals in the metformin-using group (0.8%) had been prescribed
metformin despite having an eGFR <30 mL/min/1.73 m2.
In this study cohort who had lactate measured, metformin-
treated patients compared with non-metformin-treated patients with
Type 2 diabetes were younger (P < .001), with less overall AKI
(P < .001) and less CKD (P < .001), and had lower subsequent deaths
in the time after their first lactate measure [hazard ratio (HR) 0.51;
P < .001; 95% CI 0.43-0.59]. These results suggest that metformin-
treated patients who had lactate measured had generally better
health at the time of blood sampling compared with non-metformin-
treated patients, yet their serum lactate was increased (P < .001).
Overall, the median CRP ranged from 62 to 73 mmol/L, which sug-
gests that lactate concentrations were measured during periods of
acute illness and likely sepsis.
3.2 | Lactic acidosis patient characteristics
Eighty-two individuals who developed lactic acidosis were identified
(Table 2). AKI was present in 79.3% of cases with lactic acidosis
(stage 1: 19.5%; stage 2: 30.5%; stage 3: 29.3%). The crude incidence
of lactic acidosis was 24.3 cases per 100 000 patient years (95% CI
TABLE 1 Baseline characteristics of study patients
Non-diabetic cohort
Type 2 diabetes cohort
Non-users of metformin Users of metformin
n 846 709 1037
Age (years) 74.5 (12.2) 74.4 (10.6) 70.9 (11.1)
Gender, male 56.4% 52.1% 55.9%
Deaths during study period, n (% of total deaths) 319 (37.6%) 384 (54.2%) 327 (31.5%)
Lactic acidosis cases, n (% of total of lactic acidosis
cases)
12 (14.6%) 28 (34.1%) 42 (51.2%)
Lactate (mmol/L) 1.9 (1.8) 2.4 (2.0) 2.8 (2.2)
AKI stages, n (% of cohort with each stage of AKI)
Stage 0 602 (71.1%) 350 (49.4%) 639 (61.6%)
Stage 1 137 (16.2%) 172 (24.3%) 219 (21.2%)
Stage 2 62 (7.3%) 107 (15.1%) 117 (11.3%)
Stage 3 45 (5.3%) 80 (11.3%) 62 (5.9%)
CKD stage, n (% of cohort with each stage of CKD)
Stage 1 434 (51%) 242 (34.1%) 512 (49.4%)
Stage 2 283 (33.4%) 210 (29.6%) 360 (34.7%)
Stage 3A 86 (10.2%) 110 (15.5%) 126 (12.1%)
Stage 3B 35 (4.1%) 98 (13.8%) 32 (3.1%)
Stage 4 8 (0.9%) 47(6.6%) 7 (0.7%)
Stage 5 0 (0%) 2 (0.3%) 0 (0%)
Median CRP (mmol/L) 73 (114.3) 72.5 (121.0) 62 (120.3)
HBA1c (%) N/A 8.1 (1.9) 7.9 (1.8)
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; CRP, C-reactive protein.
Data expressed as mean (SD) unless otherwise stated.
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19.5-30.1). Crude incidence rates were higher within the Type 2 dia-
betes cohort (37.9 per 100 000 patient years; 95% CI 30.0-48.0)
compared with those without diabetes (7.8 per 100 000 patient
years; 95% CI 4.4-13.7; P < .001). Within the Type 2 diabetes cohort,
those exposed to metformin had an incidence of 45.7 per 100 000
patient years (95% CI 35.9-58.3) compared with 11.8 per 100 000
patient years in patients never exposed to metformin (95% CI 4.9-
28.5, P < .001).
3.3 | Lactic acidosis mixed-effects logistic regression
A random intercept mixed logistic regression analysis was used to cal-
culate the odds ratios (ORs) for the development of lactic acidosis
(Table 3). Univariate analyses showed associations between lactic aci-
dosis and metformin use (OR 1.8; P = .011), Type 2 diabetes (OR 2.3;
P = .004) and AKI (stage 1: OR 3.2; stage 2: 9.5; stage 3: 15.9;
P < .002). CKD was not significantly associated with the development
of this condition (CKD stage 4/5; OR 2.8; P = .068); however, only
five instances of lactic acidosis occurred in patients with CKD stage
4/5, and only one was prescribed metformin.
Multivariate analysis including both those with and without Type
2 diabetes demonstrated that metformin use (OR 2.3; P = .002; 95%
CI 1.4-3.8) increased the likelihood of developing lactic acidosis
(Table 3). There was also a marked association between the develop-
ment of lactic acidosis and AKI severity. Later stages of CKD were
also associated with lactic acidosis. The presence of Type 2 diabetes
was not found to have a significant effect when included in this mul-
tivariate model (P = .26). When diabetes status was included into this
model; AKI, CKD stage 4/5 and metformin exposure continued to be
associated with the development of lactic acidosis.
A sub-cohort analysis was then performed in only those pre-
scribed metformin. Only one patient with CKD stages 4/5 devel-
oped lactic acidosis. We therefore combined this group with those
with CKD stages 3A/3B to compare those eGFR > 60 mL/min/
1.73 m2 with those with chronic impairment. A multivariate analysis
demonstrated that AKI stage 1 (OR = 3.8; P = .009; 95% CI 1.4-
10.4), stage 2 (OR 10.5; P < .001; 95% CI 3.6-30.8), stage
3 (OR 24.6; P < .001; 95% CI 7.9-75.9), CKD stages with eGFR <
60 mL/min/1.73 m2 (OR 2.7; P = .021; 95% CI 1.2-6.5) and HbA1c
(OR 1.2; P = .02; 95% CI 1.0-1.4) were associated with the develop-
ment of lactic acidosis.
3.4 | Sensitivity analysis
In a sensitivity analysis, lactic acidosis risk was assessed using a non-
mixed-effects multivariate logistic regression model. This analysis
yielded similar results to the mixed-effects model outlined in Table 3.
In this sensitivity analysis, AKI (stage 1: OR 2.8; stage 2: OR 7.7;
stage 3: OR 11.1; P = .005) and metformin use (OR 1.9; P = .002)
were associated with lactic acidosis; however, CKD stage 4/5 was
not found to be statistically significant in this model.
TABLE 2 Clinical and biochemical characteristics of patients with
incident cases of lactic acidosis (cases) and the remaining study
population (non-cases)
Lactic acidosis
cases Non-cases
n 82 2510
Age (years) 73.5 (9.5) 73.0 (11.5)
Male (%) 65.8% 54.6%
Lactate (mmol/L) 9.3 (3.5) 2.3 (1.7)
Bicarbonate (mmol/L) 11.9 (3.9) 23.5 (5.0)
Type 2 Diabetes, n (% of cohort) 70 (85.4%) 1676
(66.8%)
Users of metformin 42 (60%) 970
(57.9%)
Non-users of metformin 28 (40%) 706
(42.1%)
AKI stages, n (% of cohort with
each stage of AKI)
Stage 0 17 (20.7%) 1569
(62.5%)
Stage 1 16 (19.5%) 508
(20.2%)
Stage 2 25 (30.5%) 266 (10.6)
Stage 3 24 (29.3%) 167 (6.6%)
Baseline eGFR, n (% of cohort)
>60 mL/min/1.73 m2 59 (71.9%) 1979
(78.8%)
30-59 mL/min/1.73 m2 19 (23.2%) 468
(18.6%)
<30 mL/min/1.73 m2 4 (4.9%) 63 (2.5%)
Abbreviations: AKI, acute kidney injury; eGFR, estimated glomerular filtra-
tion rate.
Data expressed as mean (SD) unless otherwise stated.
TABLE 3 Mixed-effects logistic regression analyses assessing the
risk of lactic acidosis
Covariate OR
P-
value 95% CI
Univariate analysis
AKI Stage
1 3.2 .001 1.6-6.6
2 9.6 <.001 4.7-
19.3
3 15.9 <.001 7.7-
32.8
Metformin 1.8 .011 1.1-2.9
Type
2 Diabetes
2.3 .018 1.2-4.8
Multivariate
analysis
AKI Stage
1 3.0 .002 1.5-6.1
2 9.4 <.001 4.7-
18.8
3 16.1 <.001 7.9-
33.0
CKD Stage 4/5 3.6 .028 1.1-
11.6
Metformin 2.3 .002 1.4-3.8
Abbreviations: AKI, acute kidney injury; CI, confidence interval; OR, odds
ratio.
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3.5 | Plasma lactate concentrations
In univariate analyses, metformin use (B = 0.39 mmol/L; P < .001),
AKI (stage 1: B = 0.49 mmol/L; stage 2: B = 0.89 mmol/L: stage 3:
B = 0.94 mmol/L; P < .001), male gender (B = 0.19 mmol/L;
P = .001), Type 2 diabetes (B = 0.42 mmol/L; P < .001) and CRP
(B = 0.001 mmol/L; P < .001) were associated with higher lactate
concentrations (Table 4). No effects of CKD stage were detected
(P = .875). Lactate concentrations in the non-diabetic group, metfor-
min users and non-metformin users with Type 2 diabetes at varying
stages of AKI are shown in Figure 1.
In a multivariate analysis (Table 4), compared with patients with-
out AKI, lactate measurements increased in patients with stage
1 (B = 0.48 mmol/L; P < .001), stage 2 (B = 0.89 mmol/L; P < .001)
and stage 3 AKI (B = 0.92 mmol/L; P < .001). Additional significant
covariates included metformin use (P < .001), male gender (P = .001)
and Type 2 diabetes (P < .001). In those with type 2 diabetes, inclu-
sion of an interaction term in the model for lactate concentrations
showed an interaction between metformin exposure and AKI status
(Table 4). The effect of stage 3 AKI upon lactate concentrations was
higher in those using metformin, where the lactate measure was
0.82 mmol/L greater than those not taking metformin. Interestingly,
in the absence of AKI, metformin was not found to be statistically sig-
nificant in this model (P = .053), thereby highlighting the importance
of deranged renal function upon metformin’s capacity to increase lac-
tate concentrations.
A multivariate analysis was then performed stratified by renal
function. In those with “normal” renal function (eGFR >60 mL/min/
1.73 m2), lactate concentrations were increased in patients with stage
1 (B = 0.49 mmol/L; P < .001), stage 2 (B = 1.07 mmol/L; P < .001)
and stage 3 AKI (B = 1.04 mmol/L; P < .001). Lactate concentrations
were also independently associated with metformin use (B = 0.26
mmol/L; P = .001), Type 2 diabetes (B = 0.22 mmol/L; P = .005) and
male gender (B = 0.2 mmol/L; P = .001). In those with eGFR≤60 mL/
min/1.73 m2, only AKI (stage 1: B = 0.45 mmol/L; stage 2: B = 0.31
mmol/L; stage 3: B = 0.57 mmol/L; P < .04) and metformin use
(B = 0.57 mmol/L; P < .001) were associated with increased lactate
concentrations.
Lastly, an analysis was performed in metformin users only. A mul-
tivariate analysis showed that AKI stage 1 (B = 0.4 mmol/L; P < .001;
95% CI 0.4-0.8), stage 2 (B = 1.02 mmol/L; P < .001; 95% CI 0.7-1.3),
stage 3 (B = 1.36 mmol/L; P < .0001; 95% CI 1.02-1.71), CKD stages
4 and 5 (B = 1.8 mmol/L; P = .005; 95% CI 0.55-3.1) and HbA1c
(B = 0.05 mmol/L; P = .045; 95% CI 0.001-0.1) were associated with
higher lactate concentrations. In those with an eGFR >60 mL/min/
1.73 m2, AKI was the only significant covariate (stage 1: B = 0.66
mmol/L; stage 2: B = 1.09 mmol/L; stage 3: B = 1.19 mmol/L;
P < .001). In participants with an eGFR < 60 mL/min/1.73 m2, only
severe AKI (stage 3) was found to be significant (B = 2.0 mmol/
L; P < .001).
4 | DISCUSSION
We have undertaken a large population-based cohort study to assess
the association between metformin, AKI, and the risk of developing
lactic acidosis and high lactate concentrations. We have shown that
metformin-treated individuals are more than twice as likely to
develop this condition when compared with non-metformin-treated
individuals with or without diabetes. The impact of metformin upon
lactate concentrations is evident regardless of baseline renal function;
however, approximately 80% of lactic acidosis cases identified within
this study demonstrated evidence of AKI. Furthermore, the presence
of AKI increases the risk of lactic acidosis in a stepwise fashion with
similar trends identified when assessing lactate concentrations. An
interaction between metformin and AKI was also demonstrated, sug-
gesting the significance of acute derangements in renal function in
the context of metformin exposure. Guidelines recommend that met-
formin should be withheld in the presence of AKI, or where patients
are believed to be at risk of compromised renal function. However,
the evidence supporting this practice has been lacking. Our data pro-
vide strong evidence of this presumed association, and highlight the
significance of AKI severity in the accumulation of serum lactate and
the risk of lactic acidosis.
The crude incidence rate for lactic acidosis of 45.7 per 100 000
patient years in those exposed to metformin during the study period
TABLE 4 Lactate concentration mixed-effects analyses
Covariate Coefficient (B) P-value 95% CI
Univariate analysis
AKI Stage
1 0.49 <.001 0.38-.61
2 0.89 <.001 0.74-1.04
3 0.94 <.001 0.75-1.13
Metformin 0.39 <.001 0.28-0.51
Type 2 diabetes 0.42 <.001 1.34-1.76
Male gender 0.19 .001 1.76-2.13
CRP (mmol/L) 0.001 <.001 0.0003-0.001
Multivariate analysis
AKI Stage
1 0.48 <.001 0.36-0.60
2 0.89 <.001 0.73–1.03
3 0.92 <.001 0.74-1.11
Metformin 0.34 <.001 0.21-0.47
Male gender 0.19 .001 0.09-0.31
Type 2 diabetes 0.19 .006 0.05-0.32
Multivariate analysis (Type 2 diabetes cohort only)
AKI Stage
1 0.31 .002 0.11-0.51
2 0.67 <.001 0.43-0.90
3 0.57 <.001 0.29-0.85
Metformin 0.16 .053 −0.002-0.33
AKI*Metformin
1 0.33 .025 0.04-0.62
2 0.37 .041 0.01-0.73
3 0.82 .001 0.38-1.26
HbA1C (%) 0.04 .021 0.01-0.07
AKI, acute kidney injury; CI, confidence interval.
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is higher than those reported in recent studies, though similar rates
do appear in the literature.8,9,24,25 In 2010, Salpeter et al. published a
Cochrane review comprising data from 347 comparative studies
amounting to 70 490 patient years, which did not identify a single
case of lactic acidosis.7 However, a significant proportion of studies
excluded participants with renal dysfunction or conditions associated
with lactic acidosis, such as hepatic or cardiovascular dysfunction. It
is therefore unsurprising that no cases of this rare condition were
identified in this low-risk, well-monitored population. A major
strength of our study is the utilisation of a population-based data-
base, which is reflective of daily clinical practice with complete cap-
ture of all biochemistry in the population. Our high estimates may be
a consequence of our biochemical diagnosis of this condition from
direct assessment of laboratory investigations.
Previous studies have relied upon the interpretation of General
Practice “read codes” for the diagnosis of lactic acidosis, which may
introduce problems with diagnostic misclassification.8 Of the
82 cases that we biochemically identified, only 9 were found to
have an ICD discharge code of acidosis, and 2 further patients had
a cause of death coded as acidosis. The acidosis code includes “aci-
dosis NOS,” “lactic acidosis,” “metabolic acidosis” and “respiratory
acidosis.” There were 111 patients with acidosis codes that were
not identified as having lactic acidosis in our study. This suggests
that ICD codes are neither sensitive nor specific for identifying
cases of lactic acidosis.
We show that within the population assessed, the use of metfor-
min increases plasma lactate concentrations by 0.34 mmol/L on aver-
age, which is consistent with a previous study on lactate
concentrations in 1024 individuals with normal renal function.26 In
addition, we demonstrate that metformin is associated with an
increased risk of lactic acidosis, with those prescribed metformin
found to be more than twice as likely to receive a biochemical diag-
nosis of lactic acidosis as both individuals without diabetes and indivi-
duals receiving other treatments for diabetes. These results are
independent of other clinical parameters including CKD and AKI. Our
results also suggest that the effect of metformin may be independent
of diabetes status. However, this conclusion is limited by the absence
of metformin exposure in the non-diabetic cohort.
The largest risk factor for elevated lactate concentrations and
lactic acidosis in our study is the presence of AKI. Approximately
80% of lactic acidosis cases in this study presented with evidence of
AKI. This is seen in individuals without diabetes and participants with
Type 2 diabetes with or without metformin treatment. There is an
interaction between metformin use and AKI stage, with the largest
effect on lactate seen in those with AKI stage 3 who are also treated
with metformin. This interaction has been previously reported in a
lactic acidosis case-control study.27 Patients with Type 2 diabetes
have increased risk of AKI even following adjustments for risk factors
such as chronic renal impairment, and are therefore an “at-risk popu-
lation.”28 A previous retrospective case series of 66 patients with
metformin-associated lactic acidosis demonstrated evidence of AKI in
every patient.16 In that published cohort, metformin concentrations
correlated well with both serum creatinine and plasma lactate levels.
Careful consideration is therefore necessary before prescribing this
medication during periods of impaired renal function, such as the
development of gastroenteritis, sepsis or any intercurrent illness or
procedures where dehydration may be likely, such as endoscopy.15
There is on-going debate about the use of metformin in patients
with CKD.6 Recently, two retrospective UK studies utilising the
CPRD database have been performed. In one, an assessment of
223 968 metformin users and 34 571 patients with Type 2 diabetes
naive to metformin reported a HR of 6.37 for lactic acidosis or ele-
vated lactate concentration (>5 mmol/L) in metformin users with an
eGFR <60 mL/min/1.73 m2.8 However, in the other, a retrospective
analysis of 77 601 metformin-using patients identified a total of
35 non-fatal lactic acidosis events with no difference in incidence of
lactic acidosis between groups stratified by renal function.9 In our
study, we do show a threefold increase in the risk of lactic acidosis in
those with CKD stage 4/5. However, there was limited use of met-
formin in this CKD group who had lactates measured, which reflects
the common prescribing practices of metformin in those with chronic
renal impairment. The association observed between CKD4/5 and
Non-Diabetic Cohort
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FIGURE 1 Mean lactate concentrations with 95%
confidence intervals (CI). Participants were separated
into non-diabetic groups (left), and patients with
Type 2 diabetes who were not prescribed metformin
(centre) and those who were metformin users (right).
Mean lactate concentrations were derived from the
all lactate measurements made during the study
period within each group
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high lactate concentrations and acidosis is likely driven by the non-
metformin users, and reflects an effect of chronic renal impairment
per se rather than an interaction between metformin use and CKD.
There are a number of limitations to this study. Firstly, to be
included in the source population a lactate measurement is required.
The decision to measure lactate is likely to be biased, with a lower
threshold for lactate to be measured in those who are metformin trea-
ted. This is reflected by the fact that metformin-treated patients who
have lactate measured are younger and have less co-morbidities than
non-metformin-treated patients. However, despite this selection bias,
we show increased elevation of serum lactate concentrations and lac-
tic acidosis risk in these patients. These data could also reflect that as
the elevation of lactate is in part mediated by the direct effect of met-
formin, these patients do not need to be so sick to reach the biochem-
ical threshold defining lactic acidosis. Secondly, due to the mortality
associated with lactic acidosis, we cannot rule out the presence of sur-
vival bias. However, the impact of this is likely small, and such an
effect would have led to underestimation of disease effect sizes.
Thirdly, there were several potential confounders that could not be
directly assessed, such as the nature of patient admissions, the use of
intravenous contrast medium or the presence of contributing co-mor-
bidities, such as hepatic or cardiovascular disease. Fourthly, identifica-
tion of lactic acidosis was reliant upon using bicarbonate as a
biochemical marker of acidosis rather than direct estimates of arterial
pH. Serum bicarbonate has, however, has been validated as an alterna-
tive predictive marker to arterial base deficit.29,30 Finally, our available
data did not allow direct assessment of metformin dose or plasma
metformin concentrations, preventing the assessment of dose–
response and pharmacokinetic relationships, respectively.31,32
In this study, we utilise a population-based cohort with com-
plete capture of all incident lactate and bicarbonate measures rather
than relying on low sensitivity and specificity “read” or ICD codes.
We show that metformin use in patients with Type 2 diabetes
increases plasma lactate concentrations and the risk of lactate aci-
dosis, and that this association is particularly important in the con-
text of AKI, and can be seen even in those with normal renal
function. This study affirms and expands upon the available litera-
ture supporting this relationship, which until now has been limited
to low levels of evidence. We believe that our results provide robust
evidence to support the guidelines that patients should be aware of
this potentially harmful side-effect of metformin, and instructed to
temporarily stop taking metformin during illnesses associated with
acute renal impairment.
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